Literature DB >> 31706859

Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.

Li Zhuang1, Hai-Bo Mou2, Lan-Fang Yu2, Heng-Kai Zhu3, Zhe Yang4, Qin Liao2, Shu-Sen Zheng5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31706859     DOI: 10.1016/j.hbpd.2019.09.011

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


× No keyword cloud information.
  6 in total

Review 1.  An analysis report on the application of immune checkpoint inhibitors after liver transplantation.

Authors:  Man Xie; Zhi-Ping Dang; Xue-Guo Sun; Bei Zhang; Qun Zhang; Qiu-Ju Tian; Jin-Zhen Cai; Wei Rao
Journal:  Ther Adv Chronic Dis       Date:  2022-05-19       Impact factor: 4.970

Review 2.  Immunotherapy and Antivascular Targeted Therapy in Patients' Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge.

Authors:  Bairu Shen; Zi Guo; Peng Huang; Minghua Tan; Xiaoshen Zhang; Siyao Lin; Changshan Song; Jiaqing Wang; Minqian Huang
Journal:  J Immunol Res       Date:  2022-06-02       Impact factor: 4.493

3.  Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.

Authors:  Kang Miao; Li Zhang
Journal:  Interdiscip Sci       Date:  2021-06-21       Impact factor: 2.233

Review 4.  Immunotherapy use outside clinical trial populations: never say never?

Authors:  K Rzeniewicz; J Larkin; A M Menzies; S Turajlic
Journal:  Ann Oncol       Date:  2021-03-24       Impact factor: 51.769

Review 5.  Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.

Authors:  Shun Kawashima; Kole Joachim; Maen Abdelrahim; Ala Abudayyeh; Kenar D Jhaveri; Naoka Murakami
Journal:  Korean J Transplant       Date:  2022-06-03

Review 6.  Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.

Authors:  Yi Luo; Fei Teng; Hong Fu; Guo-Shan Ding
Journal:  World J Gastrointest Oncol       Date:  2022-01-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.